8-K: Sangamo Reports Positive Fabry Data, Q2 2025 Results

Sangamo Therapeutics announced positive topline results from its registrational STAAR study for Fabry disease, alongside its second quarter 2025 financial results, highlighting progress in its neurology pipeline.

Summary

• Positive topline results were announced from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec (ST-920), a wholly owned investigational gene therapy for adults with Fabry disease.
• A positive mean annualized estimated glomerular filtration rate (eGFR) slope of 1.965 mL/min/1.73m2/year at 52-weeks was observed across all 32 dosed patients in the STAAR study, which the U.S. Food and Drug Administration (FDA) has agreed will serve as the primary basis for approval under the Accelerated Approval pathway.
• Elevated expression of alpha-galactosidase A activity was maintained for up to 4.5 years for the longest treated patient, and plasma lyso-Gb3 levels remained generally stable following Enzyme Replacement Therapy (ERT) withdrawal.
• The first clinical site was initiated for the Phase 1/2 STAND study evaluating ST-503 for chronic neuropathic pain, with the first patient expected to be dosed in Fall 2025.
• Consolidated net loss for the second quarter ended June 30, 2025, was $20.0 million, or $0.08 per share, a significant reduction from a net loss of $36.1 million, or $0.18 per share, for the same period in 2024.
• Revenues for the second quarter ended June 30, 2025, increased to $18.3 million, compared to $0.3 million for the same period in 2024, primarily due to an upfront license payment under a capsid license agreement with Eli Lilly and Company.
• Cash and cash equivalents as of June 30, 2025, were $38.3 million, compared to $41.9 million as of December 31, 2024.
• Current cash and cash equivalents, along with proceeds from recent at-the-market offering program sales, are believed to be sufficient to fund planned operations into the fourth quarter of 2025.
• Full-year 2025 GAAP total operating expenses are reiterated to be in the range of approximately $135 million to $155 million.

Sentiment

Score: 7

Explanation: The filing presents strong positive clinical data for the Fabry disease program, including FDA alignment on the primary endpoint for accelerated approval, which is a major de-risking event. Financial results show improved revenue and reduced net loss, partly due to a significant upfront payment. However, the company's cash runway is very short (into Q4 2025), and it explicitly highlights the need for substantial additional funding or collaboration partners to continue operations, which introduces significant financial risk. The progress in the neurology pipeline is also a positive, but early-stage.

Positives

• Positive topline results from the registrational STAAR study in Fabry disease, with FDA agreement on eGFR slope as primary basis for Accelerated Approval, represent a significant step towards commercialization.
• Observed a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52-weeks across all 32 dosed patients in the STAAR study, indicating clinical benefit.
• Elevated alpha-galactosidase A activity was maintained for up to 4.5 years in the longest treated Fabry patient, suggesting durability of effect.
• Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile in the study, without the requirement for preconditioning.
• Net loss significantly decreased to $20.0 million in Q2 2025 from $36.1 million in Q2 2024, indicating improved financial performance.
• Revenues substantially increased to $18.3 million in Q2 2025 from $0.3 million in Q2 2024, driven by a significant upfront license payment from Eli Lilly and Company.
• Total GAAP operating expenses decreased to $36.2 million in Q2 2025 from $37.4 million in Q2 2024, primarily due to cost reductions from strategic realignment and lower impairment charges.
• Initiation of the first clinical site for the Phase 1/2 STAND study in chronic neuropathic pain (ST-503) marks the company's entry into clinical-stage neurology.
• Held a productive meeting with the Medicines and Healthcare products Regulatory Agency (MHRA) to discuss the prion disease study (ST-506), including alignment on nonclinical safety studies and clinical study design.

Negatives

• Cash and cash equivalents decreased to $38.3 million as of June 30, 2025, from $41.9 million as of December 31, 2024.
• Current cash and cash equivalents are only sufficient to fund planned operations into the fourth quarter of 2025, indicating a short cash runway and ongoing need for additional funding.
• Non-GAAP operating expenses increased to $33.0 million in Q2 2025 from $31.9 million in Q2 2024, partially due to an increase in clinical and manufacturing expenses related to BLA readiness activities for the Fabry disease program.

Risks

• Lack of capital resources and the need for substantial additional funding to execute the operating plan and continue as a going concern.
• Risk of being unable to obtain substantial additional funding on acceptable terms or at all, or to secure collaboration partners necessary to advance preclinical and clinical programs, particularly for the Fabry disease program, which could lead to cessation of operations or liquidation.
• Potential for collaborators and licensees to breach or terminate their agreements.
• Risk of failing to realize expected benefits from collaboration and license agreements.
• The uncertain and costly research and development process, including the risk that preclinical results may not be indicative of results in any future clinical trials.
• The effects of macroeconomic factors or financial challenges, such as ongoing overseas conflicts, tariffs, geopolitical instability, inflation, and fluctuations in interest rates, on the global business environment, healthcare systems, and Sangamo's operations.
• Impacts of clinical trial delays, pauses, and holds on clinical trial timelines and commercialization of product candidates.
• The uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects observed in preliminary clinical data from the Phase 1/2 STAAR study will not be durable or that final clinical trial data will not validate the safety and efficacy of isaralgagene civaparvovec.
• Risk that the 104-week data from the STAAR study will not verify the clinical benefit or support FDA approval, or that patients withdrawn from Enzyme Replacement Therapy (ERT) will not remain off ERT.
• The unpredictable regulatory approval process for product candidates across multiple regulatory authorities.
• Reliance on results of early clinical trials, which are not necessarily predictive of future clinical trial results.
• The potential for technological developments that could obviate technologies used by Sangamo.
• Reliance on collaborators and potential inability to secure additional collaborations.
• Inability to achieve expected future operating results.

Future Outlook

Sangamo expects to submit a Biologics License Application (BLA) for isaralgagene civaparvovec in Fabry disease as early as Q1 2026 under the Accelerated Approval pathway. The company anticipates dosing the first patient in the Phase 1/2 STAND study for chronic neuropathic pain (ST-503) in Fall 2025, with preliminary proof of efficacy data expected in late 2026. A Clinical Trial Application (CTA) submission for ST-506 in prion disease is expected as early as mid-2026. The company believes its current cash and cash equivalents, along with proceeds from recent at-the-market offerings, will fund operations into Q4 2025. Full-year 2025 GAAP operating expenses are projected to be between $135 million and $155 million, and non-GAAP operating expenses between $125 million and $145 million.

Management Comments

• "I'm proud of the progress achieved across our pipeline this quarter. The announcement of positive topline results from our registrational STAAR study in Fabry disease represented a significant step forward on our path towards commercialization for this important program." Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics.
• "This quarter we also became a clinical-stage neurology company, with the initiation of our first clinical site in the Phase 1/2 STAND study in chronic neuropathic pain. We are excited to soon dose the first patient in this study and look forward to sharing clinical data by the end of 2026." Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics.
• "We believe these data support the potential for isaralgagene civaparvovec to be a one-time, durable treatment for Fabry disease that can improve patient outcomes and will form the basis for an anticipated Biologics License Application (BLA) submission under the Accelerated Approval pathway as early as the first quarter of 2026."

Industry Context

Sangamo Therapeutics operates in the highly competitive and rapidly evolving genomic medicine and gene therapy sectors, focusing on rare diseases and neurological disorders. The positive Fabry disease data positions the company as a potential leader in gene therapy for this specific indication, leveraging the FDA's Accelerated Approval pathway. Their expansion into clinical-stage neurology with programs for chronic neuropathic pain and prion disease aligns with a broader industry trend of exploring gene and epigenetic therapies for complex neurological conditions, an area with significant unmet medical need and high commercial potential.

Stakeholder Impact

• Shareholders: Positive clinical data could increase long-term value, but the short cash runway and explicit need for further funding pose dilution risk or operational uncertainty.
• Patients (Fabry disease): Potential for a new, durable, one-time gene therapy treatment with a favorable safety profile and significant clinical benefits.
• Patients (Neurological diseases): Progress in chronic neuropathic pain and prion disease programs offers future hope for new treatment options.
• Employees: Strategic realignment and workforce reductions have occurred, but continued pipeline advancement may stabilize employment.
• Creditors/Investors: Improved financial metrics (revenue, reduced loss) are positive, but the short cash runway and explicit need for capital raise indicate ongoing financial risk.

Next Steps

• Present additional clinical data for Fabry disease at the 15th International Congress of Inborn Errors of Metabolism (ICIEM2025), September 2-6, 2025, in Kyoto, Japan.
• Engage with the FDA ahead of the planned Biologics License Application (BLA) submission for isaralgagene civaparvovec.
• Engage in business development negotiations for a potential Fabry commercialization agreement.
• Dose the first patient in the Phase 1/2 STAND study (ST-503) for chronic neuropathic pain in Fall 2025.
• Present updated nonclinical data for ST-503 at the 9th International Congress on Neuropathic Pain, September 4-6, 2025, in Berlin, Germany.
• Advance preparations for the good laboratory practice (GLP) toxicology study for ST-506.
• Anticipate Biologics License Application (BLA) submission for isaralgagene civaparvovec as early as the first quarter of 2026.
• Anticipate Clinical Trial Application (CTA) submission for ST-506 as early as mid-2026.
• Anticipate preliminary proof of efficacy data for ST-503 in late 2026.
• Participate in the Cantor Global Healthcare Conference 2025, September 3-5, 2025.
• Participate in the Wells Fargo Healthcare Conference, September 3-5, 2025.

Key Dates

Recommendation

While the positive topline data for the Fabry disease program and FDA alignment are significant de-risking events and represent a major step towards commercialization, the company's very short cash runway (into Q4 2025) and explicit need for substantial additional funding or a commercialization partner introduce considerable financial uncertainty and risk of dilution. The improved Q2 financials are largely due to a one-time license payment, and operating expenses remain high relative to cash. Investors should hold to monitor the progress of securing a Fabry commercialization agreement or additional financing, as well as the continued advancement of the neurology pipeline, before considering further investment. The clinical upside is strong, but the financial risk is material.

Keywords

Sangamo Therapeutics, SGMO, genomic medicine, gene therapy, Fabry disease, ST-920, isaralgagene civaparvovec, chronic neuropathic pain, ST-503, prion disease, ST-506, epigenetic regulation, clinical trials, FDA, MHRA, financial results, Q2 2025, biotechnology, rare disease, neurology